メリーランド州における卵巣がんの臨床試験
メリーランド州内の拠点で、卵巣がんに関する40件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/10/05更新 · NCT06995898Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University of Maryland/Greenebaum Cancer Center, Baltimore
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- 他1件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/05更新 · NCT05564377Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT04847063Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/10/02更新 · NCT01174121Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
3歳以上 · 全性別 · 2026/10/02更新 · NCT01441089Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
2歳〜100歳 · 全性別 · 2026/10/02更新 · NCT01950572Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT06885697A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Baltimore
被験者募集中第3相
18歳以上 · 女性 · 2026/10/01更新 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Maryland, Baltimore /ID# 275308, Baltimore
- Holy Cross Hospital /ID# 275872, Silver Spring
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/09/28更新 · NCT03412877A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- United Theranostics, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Maryland Oncology Hematology (MOH) ( Site 8002), Columbia
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Holy Cross Hospital, Silver Spring
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT07214779A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Greater Baltimore Medical Center, Baltimore
被験者募集中第2相
18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Greater Baltimore Medical Center, Towson
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07225270Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Holy Cross Hospital, Silver Spring
被験者募集中第3相
18歳以上 · 女性 · 2026/08/26更新 · NCT05281471Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜72歳 · 全性別 · 2026/08/13更新 · NCT02830724A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Christiana Care - Union Hospital, Elkton
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Christiana Care - Union Hospital, Elkton
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- The John Hopkins Hospital, Baltimore
- Maryland Oncology Hematology- Columbia, Rockville
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- University of Maryland, Baltimore
被験者募集中第3相
18歳以上 · 女性 · 2026/07/14更新 · NCT05804370Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Greater Baltimore Medical Center, Towson
被験者募集中第3相
18歳以上 · 女性 · 2026/07/02更新 · NCT06819007EXoPERT EMERALD Clinical Study
- John Hopkins University, Baltimore
被験者募集中観察研究健康なボランティア歓迎
45歳以上 · 全性別 · 2026/07/01更新 · NCT07186296Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA11-0, Bethesda
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT0695308918F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜120歳 · 全性別 · 2026/05/19更新 · NCT06503146Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/11更新 · NCT03968406A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT06778863CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Maryland Oncology Hematology, P.A., Annapolis
被験者募集中第2相
18歳以上 · 女性 · 2025/12/23更新 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- 他1件
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中第2相
18歳以上 · 女性 · 2025/10/27更新 · NCT06617923Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- Anne Arundel Health System, Annapolis
- Johns Hopkins University School of Medicine, Baltimore
被験者募集中観察研究
30歳以上 · 女性 · 2025/09/16更新 · NCT04794322A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- Johns Hopkins, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/05/01更新 · NCT04503265BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
被験者募集中第1相
18歳以上 · 全性別 · 2025/03/07更新 · NCT04196257ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。